These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9296228)

  • 1. Noninvasive evaluation of cardiotoxicity of 5-fluorouracil and low doses of folinic acid: a one-year follow-up study.
    Grandi AM; Pinotti G; Morandi E; Zanzi P; Bulgheroni P; Guasti L; Bertolini A; Venco A
    Ann Oncol; 1997 Jul; 8(7):705-8. PubMed ID: 9296228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patient with colorectal carcinoma.
    Meropol NJ; Petrelli NJ; Rustum YM; Rodriguez-Bigas M; Blumenson LE; Frank C; Berghorn E; Creaven PJ
    Invest New Drugs; 1995; 13(2):149-55. PubMed ID: 8617578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of 5-fluorouracil, folinic acid and recombinant alpha-2a-interferon in patients with advanced colorectal cancer.
    Ravandi F; Rytting ME; Osmon C; Braud EL; Roach RW; Edwards K; Winn R; Abbruzzese JL; Pazdur R
    Anticancer Drugs; 1999 Jul; 10(6):519-24. PubMed ID: 10885898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.
    Köhne CH; Wils J; Lorenz M; Schöffski P; Voigtmann R; Bokemeyer C; Lutz M; Kleeberg C; Ridwelski K; Souchon R; El-Serafi M; Weiss U; Burkhard O; Rückle H; Lichnitser M; Langenbuch T; Scheithauer W; Baron B; Couvreur ML; Schmoll HJ;
    J Clin Oncol; 2003 Oct; 21(20):3721-8. PubMed ID: 12963704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bolus/infusional 5-fluorouracil and folinic acid. A report on two prospective, consecutive phase II studies with 5-fluorouracil dose escalation.
    Mackean MJ; Cassidy J; Jodrell DI; Paul J; Reed NS; Canney PA; Yosef H; Habeshaw T; Robertson AG; McInnes A; Twelves CJ
    Br J Cancer; 1998 May; 77(9):1480-6. PubMed ID: 9652765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study.
    Scheithauer W; Kornek G; Marczell A; Salem G; Karner J; Kovats E; Burger D; Greiner R; Pidlich J; Schneeweiss B; Raderer M; Rosen H; Depisch D
    J Clin Oncol; 1997 Mar; 15(3):908-14. PubMed ID: 9060527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
    Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of gamma-1b-interferon in combination with fluorouracil, leucovorin, and alpha-2a-interferon.
    Grem JL; McAtee N; Murphy RF; Balis FM; Cullen E; Chen AP; Hamilton JM; Steinberg SM; Quinn M; Sorensen JM; Arbuck SG; Lawrence D; Pang J; Allegra CJ
    Clin Cancer Res; 1997 Jul; 3(7):1125-34. PubMed ID: 9815792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD).
    Aranda E; Cervantes A; Carrato A; Antón-Torres A; Massutí T; Fernández-Martos C; Díaz-Rubio E
    J Infus Chemother; 1996; 6(3):118-22. PubMed ID: 9229321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial.
    Polyzos A; Tsavaris N; Giannopoulos A; Bacoyiannis C; Papadimas V; Kalahanis N; Karatzas G; Kosmas C; Sakelaropoulos N; Archimandritis A; Papachristodoulou A; Kosmidis P
    Cancer Chemother Pharmacol; 1996; 38(3):292-7. PubMed ID: 8646806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival.
    Zaniboni A
    J Clin Oncol; 1997 Jun; 15(6):2432-41. PubMed ID: 9196159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin, and cisplatin therapy in patients with advanced colorectal cancer.
    Scheithauer W; Depisch D; Kornek G; Pidlich J; Rosen H; Karall M; Prochaska M; Ernst A; Sebesta C; Eckhardt S
    Cancer; 1994 Mar; 73(6):1562-8. PubMed ID: 8156482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer.
    Reina JJ; Aparicio J; Salvador J; Pica JM; Rueda A; Lorenzo A; de la Puente CG; Borrega P; Moreno-Nogueira JA
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):339-45. PubMed ID: 12851783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant.
    Meropol NJ; Rustum YM; Creaven PJ; Blumenson LE; Frank C
    Cancer Invest; 1999; 17(1):1-9. PubMed ID: 10999043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin.
    Klaassen U; Wilke H; Seeber S
    J Infus Chemother; 1996; 6(3):127-32. PubMed ID: 9229323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA drug approval summaries: oxaliplatin.
    Ibrahim A; Hirschfeld S; Cohen MH; Griebel DJ; Williams GA; Pazdur R
    Oncologist; 2004; 9(1):8-12. PubMed ID: 14755010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK).
    Borner MM; Castiglione M; Bacchi M; Weber W; Herrmann R; Fey MF; Pagani O; Leyvraz S; Morant R; Pestalozzi B; Hanselmann S; Goldhirsch A
    Ann Oncol; 1998 May; 9(5):535-41. PubMed ID: 9653495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic treatment options in advanced colorectal cancer: perspectives on combination 5-fluorouracil plus leucovorin.
    Grem JL
    Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-8-S18-18. PubMed ID: 9420016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial.
    Souglakos J; Vardakis N; Androulakis N; Kakolyris S; Kourousis C; Mavroudis D; Pallis A; Agelaki S; Kalbakis K; Georgoulias V
    Dig Dis; 2007; 25(1):100-5. PubMed ID: 17384515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.